APG990’s Phase 1 trial showed a 60-day half-life, supporting three- and six-month dosing. Apogee plans a 2025 Phase 1b trial comparing APG279 to Dupixent in atopic dermatitis. Our government tra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results